Our previous study revealed that, Q6, a novel analogue of TPZ, was capable of targeting hypoxic cancer cells, leading to the autophagic degradation of HIF-1α in the hypoxic HCC cells, with improved anti-cancer efficiency than its parental compound TPZ[4]. Here, HIF1A is linked to cancer.